Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation

The aim of the current study is to examine the role of serotonin on the cognitive parameters of motivation. They are embedded in a conceptual framework of motivation that merges decision-making and reinforcement learning theories. Every action is conceived as path from one state to another. The different states are associated to different values (positive for rewards and negative for punishments), and the different actions to different costs (risk, effort and delay). The tasks are designed such that the sensitivity to the state and action parameters can be inferred by fitting computational models.The primary objective is to characterize the effect of Citalopram 30mg on reward sensitivity, assessed in an incentive force task, in which participants are asked to squeeze a hand grip to win monetary rewards. Secondary objectives are to characterize the effect of Citalopram 30mg on other cognitive parameters of motivation (assessed with a motivational battery that includes rating, choice and learning tasks).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Normal Volunteers

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

CIC Neurologie GHPS

Paris, 75013, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Man or woman, age ≥ 18 and < 50
Weight between 50 kg and 90 kg.
No contraindication to effort
No evolutive pathology that could interfere with the current study signed consent
medical insurance ("sécurité sociale")

Exclusion criteria

Age < 18 or > 50
Smokers
Person under curatorship, or guardianship, or with civil rights deprivation
History of neurologic or psychiatric pathology
Presence of any psychotropic treatment
Chronic or actual consumption of alcohol, or psychotropic drugs
pregnancy, breastfeeding
Woman of childbearing potential without effective contraception
Hypersensitivity to atomoxetine or other constituents of the product
Pheochromocytoma
Narrow angle Glaucoma
Liver failure
Severe Cardiovascular Disorders
Severe Cerebrovascular Discorders
Treatment with non-selective Monoamine Oxidase Inhibitor (MAOI) : iproniazide.
Treatment with Linezoline, Lithium, Milleperthuis, Tramadol, tryptans.
Treatment with Pimozide, or treatment that can induce a QT prolongation (neuroleptics, class IA and III antiarrythmic, moxifloxacine, erythromicine, methadone, mefloquine, tricyclic antidepressants, lithium, cisapride), or treatment that can induce an hydroelectrolytic inbalance (thiazide diuretics).
Treatment with Anticoagulants
Treatment that can decrease seizure threshold: antidepressants, neuroleptics, mefloquine, buproprione, tramadol
Enzyme inducers, (rifampicine, …)
Treatment that can interfere with the performance of the subject: beta2 adrenergic agonists, analgesics, corticosteroïds, anti-inflammatory drugs, …

Treatment and study plan

Citalopram 30mg

Drug

Primary outcomes

Reward sensitivity

Time frame: Multiple Time Frame: 2h after placebo, 2h after Citalopram 30mg

Apathy will be assessed as the sensitivity to rewards in an incentive force task.

The primary Outcome measure is the change in this parameter between the placebo condition and the Citalopram condition.

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Registry information

Official study title

Etude Comparative Monocentrique, randomisée, en Cross-over, en Double Aveugle, Contre Placebo, de l'Action du Citalopram Sur Les paramètres Cognitifs de la Motivation

Acronym: MBBCitalopram

Important dates

Study start: 2014
Primary completion: 2014
Study completion: 2014
First posted: Apr 15, 2014
Registry last updated: Feb 24, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed